跳至主要内容
临床试验/NCT07627230
NCT07627230已完成不适用

Prospective Cohort Study of Genetic, Immunologic, and Environmental Risk Factors for Type 1 Diabetes in Children and Their Healthy Siblings

Privolzhsky Research Medical University1 个研究点 分布在 1 个国家目标入组 1,034 人开始时间: 2017年10月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,034
试验地点
1

研究概览

简要总结

This prospective observational cohort study evaluated genetic, immunologic, and environmental factors associated with type 1 diabetes in children. Children with newly diagnosed type 1 diabetes and their healthy siblings were enrolled between October 2017 and June 2021. Data collection included HLA class I and class II genotyping, measurement of diabetes-associated autoantibodies to insulin (IAA), glutamic acid decarboxylase (GADA), insulinoma-associated antigen-2 (IA-2A), zinc transporter 8 (ZnT8A), and islet cell antibodies (ICA), as well as C-peptide and glycated hemoglobin (HbA1c). Healthy siblings underwent annual follow-up assessments for three years, while children with type 1 diabetes were evaluated every three months during the first year after diagnosis. Information on environmental risk factors was collected using an investigator-developed questionnaire based on anamnestic data. The study aimed to identify biomarkers and risk factors associated with the development and progression of type 1 diabetes in children.

详细描述

Type 1 diabetes is a chronic autoimmune disease resulting from immune-mediated destruction of pancreatic beta cells. Genetic susceptibility, autoimmune processes, and environmental exposures are believed to contribute to disease development and progression.

This prospective observational cohort study included children with newly diagnosed type 1 diabetes and their healthy siblings. Participants were enrolled between October 2017 and June 2021. Baseline assessment included HLA class I and class II genotyping, measurement of diabetes-associated autoantibodies to insulin (IAA), glutamic acid decarboxylase (GADA), insulinoma-associated antigen-2 (IA-2A), zinc transporter 8 (ZnT8A), and islet cell antibodies (ICA), as well as C-peptide and glycated hemoglobin (HbA1c).

Children with type 1 diabetes underwent follow-up clinical and laboratory assessments every three months during the first year after diagnosis. Healthy siblings underwent annual follow-up assessments for three years, including repeated evaluation of diabetes-associated autoantibodies, C-peptide, and glycated hemoglobin. HLA genotyping was performed only at baseline.

Parents completed an investigator-developed questionnaire designed to collect anamnestic information on environmental risk factors for type 1 diabetes identified in the scientific literature. The questionnaire included data on prenatal and perinatal history, infant feeding practices, infectious diseases, family history, and other environmental exposures potentially associated with type 1 diabetes risk.

Follow-up of healthy siblings continued until January 25, 2026, through telephone contact to determine whether type 1 diabetes had developed during the observation period. The collected data were used to evaluate associations among genetic, immunologic, laboratory, and environmental factors and to identify biomarkers associated with the risk and progression of type 1 diabetes in children.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
4 Months 至 29 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • For children with newly diagnosed type 1 diabetes:
  • Age 0 to 17 years, inclusive; Diagnosis of type 1 diabetes mellitus established according to World Health Organization (WHO) diagnostic criteria applicable during the study period.
  • For healthy siblings:
  • Biological brothers or sisters of a participant with type 1 diabetes mellitus; Absence of laboratory criteria for type 1 diabetes at enrollment, including blood glucose and glycated hemoglobin (HbA1c) values below diagnostic thresholds for type 1 diabetes.
  • For all participants:
  • Written informed consent obtained from parents or legal guardians prior to study enrollment.

排除标准

  • Monogenic diabetes mellitus; Secondary diabetes mellitus; Refusal or withdrawal of informed consent.

研究者

发起方
Privolzhsky Research Medical University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Anastasia E. Bolshakova

Associate Professor

Privolzhsky Research Medical University

研究点 (1)

Loading locations...

相似试验